Anhui Provincial laboratory of inflammatory and immunity Disease, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei 230032, China; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Medical University, Hefei 230032, China.
School of International Education, Anhui Medical University, Hefei 230032, China.
Biomed Pharmacother. 2024 Aug;177:116898. doi: 10.1016/j.biopha.2024.116898. Epub 2024 Jun 14.
Liver disease affects millions of people in the world, and China has the highest prevalence of liver disease in the world. Small ubiquitin-related modifier (SUMO) modification is a highly conserved post-translational modification of proteins. They are widely expressed in a variety of tissues, including the heart, liver, kidney and lung. SUMOylation of protein plays a key role in the occurrence and development of liver disease. Therefore, this study reviewed the effects of SUMO protein on non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease (ALD), viral hepatitis, hepatic fibrosis (HF), hepatocellular carcinoma (HCC), and other liver diseases to provide novel strategies for targeted treatment of liver disease.
肝脏疾病影响着全球数百万人,而中国是全球肝脏疾病发病率最高的国家。小泛素相关修饰物 (SUMO) 修饰是一种高度保守的蛋白质翻译后修饰。它们广泛表达于多种组织中,包括心脏、肝脏、肾脏和肺部。蛋白质的 SUMO 化在肝脏疾病的发生和发展中起着关键作用。因此,本研究综述了 SUMO 蛋白对非酒精性脂肪性肝病 (NAFLD)、酒精性肝病 (ALD)、病毒性肝炎、肝纤维化 (HF)、肝细胞癌 (HCC) 和其他肝脏疾病的影响,为肝脏疾病的靶向治疗提供了新策略。